A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Diagnostic tools based on artificial intelligence are now making their way into Norwegian hospitals. AI can independently read X-ray images and detect bone fractures, or assess cancer tumors in both ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Details on ...

Researchers have developed a simple new tool that can identify the risk level of metastatic prostate cancer patients earlier. At the time of diagnosis, the test can predict how well the patient will ...

Early detection of recurrent prostate cancer using 18F-DCFPyL PET/CT PET/CT in patients with minimal PSA levels. Patient, companion, and physician survey questions and results.

PANAMA CITY, Fla. (WJHG/WECP) - Hope Regional Medical Center in Panama City is now using a powerful new diagnostic tool in the fight against Prostate Cancer. Doctors at the center have always used CT ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

“This study adjusted for testosterone levels, which can influence PSA and outcomes, and still found a significant association. This strengthens the argument that PSA response to neoadjuvant therapy is ...